Sarasota Memorial Health Care System has been recognized as one of the nation’s “Best Workplaces for Nurses 2026” by Nursegrid, a leading digital platform serving more than 650,000 nurses nationwide.
Sarasota Memorial Health Care System (SMH) has enrolled the first patient in a clinical study evaluating the safety and effectiveness of a novel, minimally invasive treatment for papillary thyroid cancer (PTC) using Pulse Biosciences’ nPulse™ technology.
Sarasota Memorial is one of two research sites evaluating the effectiveness of a novel, minimally invasive treatment for papillary thyroid cancer. The study is led locally by Ralph P. Tufano, MD, MBA, FACS, thyroid and parathyroid surgeon with Sarasota Memorial’s Brian D. Jellison Cancer Institute, in collaboration with SMH’s Kolschowsky Research and Education Institute and principal investigator Victoria Banuchi, M.D., associate professor of Head & Neck Surgery at The University of Texas MD Anderson Cancer Center. A total of 30 patients will be enrolled across the two study sites.
That three pounds of thinking inside your skull may be 60% fatty tissue but it’s far from lazy, capable of transmitting information through the body faster than 250mph and powering a 25-watt bulb.
See construction updates and notifications as progress continues on the SMH-North Port Hospital Campus.
